Literature DB >> 34582783

Aducanumab and the "post-amyloid" era of Alzheimer research?

Erik S Musiek1, David A Bennett2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34582783      PMCID: PMC9308468          DOI: 10.1016/j.neuron.2021.09.007

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   18.688


× No keyword cloud information.
  11 in total

1.  Donanemab in Early Alzheimer's Disease.

Authors:  Mark A Mintun; Albert C Lo; Cynthia Duggan Evans; Alette M Wessels; Paul A Ardayfio; Scott W Andersen; Sergey Shcherbinin; JonDavid Sparks; John R Sims; Miroslaw Brys; Liana G Apostolova; Stephen P Salloway; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2021-03-13       Impact factor: 91.245

2.  Neuropathology of older persons without cognitive impairment from two community-based studies.

Authors:  D A Bennett; J A Schneider; Z Arvanitakis; J F Kelly; N T Aggarwal; R C Shah; R S Wilson
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

3.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation.

Authors:  Zhuohao He; Jing L Guo; Jennifer D McBride; Sneha Narasimhan; Hyesung Kim; Lakshmi Changolkar; Bin Zhang; Ronald J Gathagan; Cuiyong Yue; Christopher Dengler; Anna Stieber; Magdalena Nitla; Douglas A Coulter; Ted Abel; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2017-12-04       Impact factor: 53.440

4.  The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962

5.  Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies.

Authors:  Patricia A Boyle; Lei Yu; Sue E Leurgans; Robert S Wilson; Ron Brookmeyer; Julie A Schneider; David A Bennett
Journal:  Ann Neurol       Date:  2018-12-19       Impact factor: 10.422

6.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Authors:  John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun
Journal:  Arch Neurol       Date:  2009-12

Review 7.  Molecular genetics of Alzheimer disease amyloid.

Authors:  R E Tanzi; P S George-Hyslop; J F Gusella
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

8.  Person-specific contribution of neuropathologies to cognitive loss in old age.

Authors:  Patricia A Boyle; Lei Yu; Robert S Wilson; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

9.  Cortical Proteins Associated With Cognitive Resilience in Community-Dwelling Older Persons.

Authors:  Lei Yu; Shinya Tasaki; Julie A Schneider; Konstantinos Arfanakis; Duc M Duong; Aliza P Wingo; Thomas S Wingo; Nicola Kearns; Gregory R J Thatcher; Nicholas T Seyfried; Allan I Levey; Philip L De Jager; David A Bennett
Journal:  JAMA Psychiatry       Date:  2020-11-01       Impact factor: 21.596

Review 10.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

View more
  2 in total

1.  Brain network modulation in Alzheimer's disease: clinical phenotypes and windows of opportunity.

Authors:  Lorenzo Pini
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 2.  Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease.

Authors:  Da Hae Jung; Gowoon Son; Oh-Hoon Kwon; Keun-A Chang; Cheil Moon
Journal:  Pharmaceutics       Date:  2022-07-22       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.